INMB
Inmune Bio, Inc.Company Information
- Company Name
- Inmune Bio, Inc.
- CIK
- CIK0001711754
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- INMB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- INMB
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-09-30
- Last sale
- 2023-07-12
- Shares purchased (TTM)
- 125,152
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,102,270
- Shares outstanding
- 26,718,507
- Ownership
- 15.35%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 21.99%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 18 | 21 | 25 | 28 | 33 | 19 | 21 | 34 | 31 | 26 | 36 | 42 | ||||||
| Accounts Receivable Net Current | 4 | 0 | 4 | 2 | 2 | 1 | 1 | 1 | 3 | - | 2 | - | ||||||
| Other Receivables Net Current | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | ||||||
| Assets Current | 24 | 23 | 30 | 31 | 36 | 21 | 23 | 36 | 35 | 30 | 40 | 46 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | 17 | 17 | 17 | 17 | 17 | 17 | 17 | ||||||
| Assets | 27 | 26 | 32 | 33 | 38 | 38 | 40 | 53 | 52 | 47 | 57 | 63 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 5 | 5 | 8 | 7 | 8 | 7 | 7 | 11 | 9 | 9 | 8 | 4 | ||||||
| Other Liabilities Current | - | - | - | - | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Other Long Term Debt Current | - | - | - | - | - | - | - | - | - | - | - | 10 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | - | 2 | 5 | 7 | 10 | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 6 | 5 | 8 | 7 | 9 | 8 | 7 | 14 | 15 | 17 | 18 | 14 | ||||||
| Other Long Term Debt Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 2 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 6 | 6 | 9 | 8 | 9 | 8 | 7 | 14 | 15 | 18 | 19 | 18 | ||||||
Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 238 | 235 | 233 | 230 | 227 | 203 | 196 | 194 | 179 | 161 | 159 | 157 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -216 | -214 | -209 | -204 | -197 | -173 | -163 | -154 | -142 | -132 | -121 | -113 | ||||||
| Stockholders Equity | 20 | 20 | 24 | 25 | 29 | 30 | 32 | 39 | 36 | 28 | 37 | 44 | ||||||
| Liabilities And Stockholders Equity | 27 | 26 | 32 | 33 | 38 | 38 | 40 | 53 | 52 | 47 | 57 | 63 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | - | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | - | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 28 | 27 | 27 | 27 | 27 | 23 | 22 | 22 | 20 | 18 | 18 | 18 | ||||||
| Shares Outstanding | 28 | 27 | 27 | 27 | 27 | 23 | 22 | 22 | 20 | 18 | 18 | 18 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialInmune Bio, Inc. (INMB) — SEC Financial Statements & Analysis
Inmune Bio, Inc. (INMB) is a biological products, (no diagnostic substances) company, incorporated in NV. Inmune Bio, Inc. trades on Nasdaq as: INMB. Inmune Bio, Inc. (INMB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Inmune Bio, Inc. carries a market cap of $43.55M, a P/E ratio of -2.36x, a P/B ratio of 2.14x, a P/S ratio of 772.44x, an enterprise value of $25.14M, and an EV/EBITDA multiple of -1.26x. On profitability, it posts an operating margin of -94766.00%, a net margin of -91866.00%, a Return on Equity (ROE) of -74.82%, a Return on Assets (ROA) of -57.08%, and a Return on Invested Capital (ROIC) of -414.87%. Per share, it reports EPS of $-0.69, diluted EPS of $-0.69, free cash flow per share of $-0.57, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -66.82% year-over-year, and EPS growth of -71.07% year-over-year. On the balance sheet, it maintains a current ratio of 4.04x, a quick ratio of 3.94x, working capital of $17.91M, a debt-to-equity ratio of 0.32x, a debt ratio of 0.24, free cash flow of $-15.30M (TTM), and net debt of $-18.41M. Figures sourced from SEC EDGAR.
- Market Cap
- $43.55M
- P/E TTM
- -2.36x
- EPS TTM
- $-0.69
- P/B TTM
- 2.14x
- ROE TTM
- -74.82%
- ROA TTM
- -57.08%
- Debt To Equity
- 0.32x
- Free Cash Flow TTM
- $-15.30M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Inmune Bio, Inc. in?
Inmune Bio, Inc. (INMB) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does INMB trade on?
Inmune Bio, Inc. (INMB) trades on the Nasdaq.
Where is Inmune Bio, Inc. incorporated?
Inmune Bio, Inc. is incorporated in NV.
When was Inmune Bio, Inc. (INMB)'s most recent SEC filing?
Inmune Bio, Inc. (INMB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is INMB's market cap?
Inmune Bio, Inc. (INMB) has a market capitalization of $43.55M as of 2026-06-30.
What is INMB's EPS (earnings per share)?
Inmune Bio, Inc. (INMB)'s trailing twelve month EPS is $-0.69 as of 2026-06-30.
What is INMB's ROE (return on equity)?
Inmune Bio, Inc. (INMB)'s trailing twelve month Return on Equity (ROE) is -74.82% as of 2026-06-30.
What is INMB's ROA (return on assets)?
Inmune Bio, Inc. (INMB)'s trailing twelve month Return on Assets (ROA) is -57.08% as of 2026-06-30.
What is INMB's ROIC (return on invested capital)?
Inmune Bio, Inc. (INMB)'s trailing twelve month Return on Invested Capital (ROIC) is -414.87% as of 2025-03-31.
What is INMB's EV/EBITDA?
Inmune Bio, Inc. (INMB)'s trailing twelve month EV/EBITDA is -1.26x as of 2026-06-30.